Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
13 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Aptevo Therapeutics Inc.’s names, not what it holds today.
Patents granted
13
13 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 1 in 2024 and 1 in 2023
Applications published
24
since 2001, to Dec 31, 2025
Names they are printed under
2
a subsidiary
By yearGrantedApplications published
'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
APTEVO RESEARCH AND DEVELOPMENT LLC a subsidiary
named as the applicant on its applications, in US
23 publishedAptevo Research and Development LLC a subsidiary
US, as the owner printed on each patent
1 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Oct 14, 2025 | 12,441,798 | CD123 binding proteins and related compositions and methods | Biotechnology | Aptevo Research and Development LLC |
| Mar 26, 2024 | 11,939,392 | CD123 binding proteins and related compositions and methods | Biotechnology | Aptevo Research and Development LLC |
| Aug 15, 2023 | 11,725,060 | Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods | Biotechnology | Aptevo Research and Development LLC |
| Jun 7, 2022 | 11,352,426 | CD3 binding polypeptides | Biotechnology | Aptevo Research and Development LLC |
| Apr 26, 2022 | 11,312,786 | Oncofetal antigen binding proteins and related compositions and methods | Biotechnology | Aptevo Research and Development LLC |
| Feb 8, 2022 | 11,242,400 | CD123 binding proteins and related compositions and methods | Biotechnology | Aptevo Research and Development LLC |
| Jun 9, 2020 | 10,676,533 | Methods of treatment of CD123 overexpressing disorders | Biotechnology | Aptevo Research and Development LLC |
| Jun 4, 2019 | 10,307,481 | CD37 immunotherapeutics and uses thereof | Pharmaceuticals | Aptevo Research and Development LLC |
| Mar 26, 2019 | 10,239,949 | Oncofetal antigen binding proteins and related compositions and methods | Biotechnology | Aptevo Research and Development LLC |
| Feb 12, 2019 | 10,202,452 | CD3 binding polypeptides | Biotechnology | Aptevo Research and Development LLC |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Oct 17, 2024 | 2024/0343801 | CD123 BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS | Biotechnology | APTEVO RESEARCH AND DEVELOPMENT LLC · patent 12,441,798 granted from it |
| Sep 12, 2024 | 2024/0301086 | TUMOR-ASSOCIATED ANTIGENS AND CD3-BINDING PROTEINS, RELATED COMPOSITIONS, AND METHODS | Pharmaceuticals | APTEVO RESEARCH AND DEVELOPMENT LLC |
| Aug 8, 2024 | 2024/0262920 | DOSING REGIMENS FOR PROTEIN THERAPEUTICS | Pharmaceuticals | APTEVO RESEARCH AND DEVELOPMENT LLC |
| May 9, 2024 | 2024/0150483 | COMPOSITIONS COMPRISING 4-1BB and OX40 BINDING PROTEINS AND METHODS OF USE | Pharmaceuticals | APTEVO RESEARCH AND DEVELOPMENT LLC |
| Sep 28, 2023 | 2023/0303720 | FORMULATIONS FOR PROTEIN THERAPEUTICS | Pharmaceuticals | APTEVO RESEARCH AND DEVELOPMENT LLC |
| May 18, 2023 | 2023/0151102 | METHODS AND COMPOSITIONS FOR PREVENTING ADSORPTION OF THERAPEUTIC PROTEINS TO DRUG DELIVERY SYSTEM COMPONENTS | Pharmaceuticals | APTEVO RESEARCH AND DEVELOPMENT LLC |
| Nov 17, 2022 | 2022/0363773 | CD123 BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS | Biotechnology | APTEVO RESEARCH AND DEVELOPMENT LLC · patent 11,939,392 granted from it |
| Aug 4, 2022 | 2022/0242962 | 4-1BB AND OX40 BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS, ANTIBODIES AGAINST 4-1BB, ANTIBODIES AGAINST OX40 | Biotechnology | APTEVO RESEARCH AND DEVELOPMENT LLC |
| Apr 1, 2021 | 2021/0095046 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS | Pharmaceuticals | APTEVO RESEARCH AND DEVELOPMENT LLC |
| Nov 12, 2020 | 2020/0354447 | SINGLE-CHAIN MULTIVALENT BINDING PROTEINS WITH EFFECTOR FUNCTION | Pharmaceuticals | APTEVO RESEARCH AND DEVELOPMENT LLC |
What it applied for, 2024 to 2025: Pharmaceuticals 3 · Biotechnology 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.